Cargando…
A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer
BACKGROUND: Prognosis among patients with differentiated thyroid cancer is widely variable. Better understanding of biologic subtypes is necessary to stratify patients and improve outcomes. METHODS: In patients diagnosed with classic histology papillary thyroid cancer treated from 1973 to 2009, BRAF...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346248/ https://www.ncbi.nlm.nih.gov/pubmed/30552739 http://dx.doi.org/10.1002/cam4.1857 |
_version_ | 1783389727090540544 |
---|---|
author | Lin, Alexander J. Samson, Pamela DeWees, Todd Henke, Lauren Baranski, Thomas Schwarz, Julie Pfeifer, John Grigsby, Perry Markovina, Stephanie |
author_facet | Lin, Alexander J. Samson, Pamela DeWees, Todd Henke, Lauren Baranski, Thomas Schwarz, Julie Pfeifer, John Grigsby, Perry Markovina, Stephanie |
author_sort | Lin, Alexander J. |
collection | PubMed |
description | BACKGROUND: Prognosis among patients with differentiated thyroid cancer is widely variable. Better understanding of biologic subtypes is necessary to stratify patients and improve outcomes. METHODS: In patients diagnosed with classic histology papillary thyroid cancer treated from 1973 to 2009, BRAF V600E mutation status was determined on surgical tumor specimens by restriction fragment length polymorphism analysis. A tissue microarray (TMA) was constructed from tumor specimens in triplicate and stained by immunohistochemistry for RET, phospho‐MEK, MAPK(dpERK), PPARγ, and phospho‐AKT(pAKT). Stained slides were scored independently and blindly by two investigators and compared to tumor and patient characteristics and outcomes. RESULTS: A total of 231 patients had archived formalin‐fixed, paraffin‐embedded tumor tissue available and were included on the TMA. Mean age at diagnosis was 44 years (range 6‐82 years); proportion of patients with female sex was (72%); 2015 American Thyroid Association (ATA) risk stratification was low (26%), intermediate (32%), and high (42%). BRAF V600E mutation was found in 74% of specimens, and IHC was scored as positive for RET (61%), MAPK (dpERK) (14%), PPARγ (27%), and pAKT (39%). Positive RET staining was associated with a lower risk of recurrence (HR = 0.46, 95% CI 0.22‐0.96). No other molecular biomarkers were independent predictors of recurrence on univariable analysis. On RPA, patients with RET‐negative and either MAPK(dpERK)‐positive or pAKT‐positive tumors were identified to have a high risk of recurrence (HR = 5.4, 95%CI 2.5‐11.7). This profile remained associated with recurrence in a multivariable model including ATA risk stratification (HR = 2.8, 95% CI 1.3‐6.0). CONCLUSION: Characterization of molecular pathways involved in cPTC tumorigenesis may add further risk stratification for recurrence beyond the 2015 ATA risk categories alone. |
format | Online Article Text |
id | pubmed-6346248 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63462482019-01-29 A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer Lin, Alexander J. Samson, Pamela DeWees, Todd Henke, Lauren Baranski, Thomas Schwarz, Julie Pfeifer, John Grigsby, Perry Markovina, Stephanie Cancer Med Cancer Prevention BACKGROUND: Prognosis among patients with differentiated thyroid cancer is widely variable. Better understanding of biologic subtypes is necessary to stratify patients and improve outcomes. METHODS: In patients diagnosed with classic histology papillary thyroid cancer treated from 1973 to 2009, BRAF V600E mutation status was determined on surgical tumor specimens by restriction fragment length polymorphism analysis. A tissue microarray (TMA) was constructed from tumor specimens in triplicate and stained by immunohistochemistry for RET, phospho‐MEK, MAPK(dpERK), PPARγ, and phospho‐AKT(pAKT). Stained slides were scored independently and blindly by two investigators and compared to tumor and patient characteristics and outcomes. RESULTS: A total of 231 patients had archived formalin‐fixed, paraffin‐embedded tumor tissue available and were included on the TMA. Mean age at diagnosis was 44 years (range 6‐82 years); proportion of patients with female sex was (72%); 2015 American Thyroid Association (ATA) risk stratification was low (26%), intermediate (32%), and high (42%). BRAF V600E mutation was found in 74% of specimens, and IHC was scored as positive for RET (61%), MAPK (dpERK) (14%), PPARγ (27%), and pAKT (39%). Positive RET staining was associated with a lower risk of recurrence (HR = 0.46, 95% CI 0.22‐0.96). No other molecular biomarkers were independent predictors of recurrence on univariable analysis. On RPA, patients with RET‐negative and either MAPK(dpERK)‐positive or pAKT‐positive tumors were identified to have a high risk of recurrence (HR = 5.4, 95%CI 2.5‐11.7). This profile remained associated with recurrence in a multivariable model including ATA risk stratification (HR = 2.8, 95% CI 1.3‐6.0). CONCLUSION: Characterization of molecular pathways involved in cPTC tumorigenesis may add further risk stratification for recurrence beyond the 2015 ATA risk categories alone. John Wiley and Sons Inc. 2018-12-14 /pmc/articles/PMC6346248/ /pubmed/30552739 http://dx.doi.org/10.1002/cam4.1857 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Prevention Lin, Alexander J. Samson, Pamela DeWees, Todd Henke, Lauren Baranski, Thomas Schwarz, Julie Pfeifer, John Grigsby, Perry Markovina, Stephanie A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer |
title | A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer |
title_full | A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer |
title_fullStr | A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer |
title_full_unstemmed | A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer |
title_short | A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer |
title_sort | molecular approach combined with american thyroid association classification better stratifies recurrence risk of classic histology papillary thyroid cancer |
topic | Cancer Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346248/ https://www.ncbi.nlm.nih.gov/pubmed/30552739 http://dx.doi.org/10.1002/cam4.1857 |
work_keys_str_mv | AT linalexanderj amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT samsonpamela amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT deweestodd amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT henkelauren amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT baranskithomas amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT schwarzjulie amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT pfeiferjohn amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT grigsbyperry amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT markovinastephanie amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT linalexanderj molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT samsonpamela molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT deweestodd molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT henkelauren molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT baranskithomas molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT schwarzjulie molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT pfeiferjohn molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT grigsbyperry molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer AT markovinastephanie molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer |